Added to YB: 2025-01-07
Pitch date: 2024-11-11
ACE.ST [bullish]
Ascelia Pharma AB (publ)
-69.51%
current return
Author Info
SmallPharma shares investment research in Micro & Small Caps with clear catalyst, mainly small pharma after phase II & III. Sign up for the newsletter.
Company Info
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.
Market Cap
SEK 107.9M
Pitch Price
SEK 2.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.07
P/E
-1.38
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Ascelia Pharma - multibagger in the making
ACE.ST: Orviglance MRI agent for kidney-impaired patients post-successful Phase III. 800M USD global market, no competitors in niche. FDA submission mid-2025. 24M USD market cap (7.5M cash) vs. potential 10x M&A value. Risks: commercialization deal terms, regulatory timeline.
Read full article (33 min)